Synthetic Genomics, United Therapeutics, Lung Biotech ally in organ transplants
Executive Summary
In a multi-year agreement, Synthetic Genomics Inc. (SGI; DNA-based products) is partnering with United Therapeutics Corp. and its Lung Biotechnology Inc. subsidiary to use synthetic genomics in the development of humanized pig organs for patients who will receive lung transplants.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Transgenics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice